The Community Outreach group at Cleveland Clinic’s Taussig Cancer Center sought input from people at local faith-based organizations to better understand and address the history of health disparities in the community.
Could Immunotherapy Help Cure Cutaneous Squamous Cell Carcinoma?
The phase 3 KEYNOTE-630 trial has begun enrolling patients with high-risk, locally advanced cutaneous squamous cell carcinoma (cSCC) to evaluate the curative potential of PD-1 inhibitor pembrolizumab.
New Renal Cancer Therapy Effective in Higher Risk Groups
Pembrolizumab plus axitinib is another effective option for treating renal cell carcinoma, indicates the KEYNOTE-426 study.
Optimal Total Dose of Cisplatin for High-Risk Oral Cavity Squamous Cell Carcinoma
In high-risk resected oral cavity squamous cell carcinoma, median disease-free survival doubles when patients receive 200 mg/m2 or more of cisplatin along with radiation therapy, shows one study.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Don’t Miss These Cleveland Clinic Cancer Center Presentations at the 2019 ASCO Annual Meeting
See these presentations by Cleveland Clinic Cancer Center staff at ASCO 2019.
How Are You Achieving Reductions in Time to Treat for Colorectal, Breast and GI Cancers?
With time to treat rising nationally, Cleveland Clinic is seeing reductions. How? Get the answer from Digestive Disease & Surgery Institute Chairman Conor Delaney, MD, PhD, in our “The Short Answer” series.
Top 10 ASCO Abstracts 2016
Top 10 favorite abstracts from ASCO 2016, chosen by Cleveland Clinic’s Hematologists and Medical Oncologists
Chemotherapy, Exercise and BMI Best Predictors of Symptoms in Breast Cancer Survivorship Analysis
Breast cancer survivors treated with chemotherapy were much more likely to experience long-term symptoms than those who did not receive chemotherapy, a Cleveland Clinic analysis finds.
Tumor PD-L1 Expression Predicts Benefit from PD-1/PD-L1 Inhibition
Analysis finds tumor PD-L1 expression with a 5 percent cutoff is a reliable predictor of treatment success with PD-1/PD-L1 checkpoint inhibitors in the treatment of lung and other hard-to-treat cancers.
New Pancreatic Cancer Treatment Guidelines Should Improve Care
The diagnosis and treatment of pancreatic cancer remains challenging, with no screening programs and relatively little progress in improving survival rates. In an effort to standardize care and address knowledge gaps, the American Society of Clinical Oncology has issued new treatment guidelines for potentially curable, locally advanced and metastatic pancreatic cancer. Cleveland Clinic Cancer Center oncologists helped lead the effort.